Immutep snaffles A$3.6M from French government for R&D

The Market Herald09-24

Biotech company Immutep Ltd (ASX:IMM) has received a R&D Tax Incentive of around A$3.6 million from the French Government to boost development of two current product candidates. The incentive – worth ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2469846881?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-24 08:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2469846881","market":"us","top_or_hot":-1,"title":"Immutep snaffles A$3.6M from French government for R&D","media":"The Market Herald","content":"<div>\n<p>Biotech company Immutep Ltd (ASX:IMM) has received a R&D Tax Incentive of around A$3.6 million from the French Government to boost development of two current product candidates.\nThe incentive – worth ...</p>\n\n<a href=\"https://themarketonline.com.au/immutep-snaffles-a3-6m-from-french-government-for-rd-2024-09-24/\">Source Link</a>\n\n</div>\n","source":"markerherald_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Immutep snaffles A$3.6M from French government for R&D</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmutep snaffles A$3.6M from French government for R&D\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-24 08:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://themarketonline.com.au/immutep-snaffles-a3-6m-from-french-government-for-rd-2024-09-24/><strong>The Market Herald</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biotech company Immutep Ltd (ASX:IMM) has received a R&D Tax Incentive of around A$3.6 million from the French Government to boost development of two current product candidates.\nThe incentive – worth ...</p>\n\n<a href=\"https://themarketonline.com.au/immutep-snaffles-a3-6m-from-french-government-for-rd-2024-09-24/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"APC.AU","symbol_name":"AUSTRALIAN POTASH LTD","start_time":0,"source_url":"https://themarketonline.com.au/immutep-snaffles-a3-6m-from-french-government-for-rd-2024-09-24/","article_id":"2469846881","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2469846881","pubTimestamp":1727136660,"sourceInfo":{"source_id":"markerherald_stock","name":"The Market Herald"},"weMediaInfo":null,"summary":"Biotech company Immutep Ltd  has received a R&D Tax Incentive of around A$3.6 million from the French Government to boost development of two current product candidates.The incentive – worth 2,194,918 – was provided under the government’s Crédit d’Impt Recherche scheme  – for which Immutep is eligible due to activities carried out at its laboratory in France.Under the scheme, companies can be reimbursed 30% of their eligible expenditure on research and development activities. In this case, Immutep will be plugging it into global clinical development of candidates eftilagimod alpha and IMP761.These are candidates central to the company’s mission to develop Lymphocyte Activation Gene -3 immunotherapies for cancer and autoimmune diseases.Eftilagimod alpha is Immutep’s proprietary soluble LAG-3 clinical stage candidate which is a first-in-class antigen presenting cell  activator for the treatment of cancer, while IMP761 is a first-in-class immunosuppressive agonist antibody to LAG-3.Immutep","collect":0,"end_time":0,"defaultTopTitle":"themarketonline.com.au","property":[],"viewcount":null,"language":"en","relate_stocks":{"APC.AU":"AUSTRALIAN POTASH LTD","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU1366333091.USD":"FIDELITY GLOBAL FOCUS \"A\" (USD) ACC","BK7067":"生物科技","CIR":"Circor国际","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU0077335932.USD":"FIDELITY AMERICAN GROWTH \"A\" INC","LU0157215616.USD":"FIDELITY GLOBAL FOCUS \"A\" INC","IMM.AU":"IMMUTEP LTD","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","BK4161":"工业机械","APC":"阿纳达科石油","BK7095":"多种金属与采矿","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","BK7508":"医药生物股"},"translate_title":"Immutep从法国政府获得360万澳元用于研发","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APC":1,"APC.AU":1,"CIR":1,"IMM.AU":1},"content_text":"Biotech company Immutep Ltd (ASX:IMM) has received a R&D Tax Incentive of around A$3.6 million from the French Government to boost development of two current product candidates.\nThe incentive – worth €2,194,918 – was provided under the government’s Crédit d’Impôt Recherche scheme (CIR) – for which Immutep is eligible due to activities carried out at its laboratory in France.\nUnder the scheme, companies can be reimbursed 30% of their eligible expenditure on research and development activities. In this case, Immutep will be plugging it into global clinical development of candidates eftilagimod alpha and IMP761.\nThese are candidates central to the company’s mission to develop Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. \nEftilagimod alpha is Immutep’s proprietary soluble LAG-3 clinical stage candidate which is a first-in-class antigen presenting cell (APC) activator for the treatment of cancer, while IMP761 is a first-in-class immunosuppressive agonist antibody to LAG-3.\nImmutep shares rose on the news, but as of 12:45 AEST, they are trading flat at 34.5 cents.\nJoin the discussion: See what Hot Copper users are saying about Immutep and be part of the conversations that move the markets.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2469846881"}